US-based biotechnology company Genalyte closed a $44m series C round on Tuesday featuring biotechnology real estate company BioMed Realty’s corporate venturing unit, BioMed Realty Ventures.
Venture capital firm Khosla Ventures led the round, which also included Redmile Group and Claremont Creek Ventures.
Founded in 2007, Genalyte’s Maverick Detection System enables general practitioners to run blood tests by putting a single drop of blood on a microchip. The technology can be used in the surgery and provides results within 15 minutes.
…